Oncology Billing Experts

Oncology Medical Billing Services

Oncology billing is among the most complex in medicine, driven by chemotherapy drug administration codes, infusion time tracking, and constantly changing drug regimens.

Get Your Free Assessment Explore the Guide
Oncology Medical Billing Services
200+

Oncology Practices

98.2%

Clean Claim Rate

$8.5M

Revenue Recovered

48hr

Drug Claims

Overview

The High-Stakes Complexity of Oncology Billing

Oncology billing is among the most complex in medicine, driven by chemotherapy drug administration codes, infusion time tracking, and constantly changing drug regimens. Chemotherapy administration (96401-96549) requires precise documentation of infusion start and stop times, with separate codes for initial administration, sequential infusions, and concurrent infusions during the same session.

Drug reimbursement under Medicare Part B (J-codes) requires practices to purchase medications upfront and bill after administration. The gap between acquisition cost and reimbursement, known as the Average Sales Price methodology, can create significant cash flow challenges for oncology practices.

The High-Stakes Complexity of Oncology Billing
Challenges

Common Oncology billing Challenges We Solve

Every Oncology billing team deals with payer delays, coding nuance, and collection leakage.

Chemotherapy Drug Code Changes

HCPCS J-codes for oncology drugs update quarterly. New biosimilars, dose-based code changes, and NDC-to-HCPCS crosswalk updates mean that billing staff must stay current or risk submitting claims with incorrect drug codes.

Infusion Administration Hierarchy

Chemotherapy infusion billing follows a strict hierarchy: initial infusion (96413), sequential infusion (96415), concurrent infusion (96417), and push codes (96409, 96411). Violating the hierarchy triggers automatic denials.

Drug Acquisition Cost Recovery

Oncology practices purchase high-cost drugs and bill payers for reimbursement. The gap between acquisition cost and reimbursement (ASP+6% for Medicare) must be managed carefully to avoid financial losses on expensive drug regimens.

Treatment Plan Authorization Complexity

Multi-cycle chemotherapy regimens require ongoing prior authorization. Each cycle, drug change, or dose adjustment may trigger a new authorization requirement. Missing a single authorization can result in zero reimbursement for a $10,000+ treatment session.

Services

Complete Oncology billing Services

Support spans the full revenue cycle.

Chemotherapy and immunotherapy drug billing (J-codes, Q-codes)

Infusion administration hierarchy coding (96413-96417, 96409-96411)

Drug acquisition cost tracking and ASP reimbursement analysis

Prior authorization for treatment regimens and cycle renewals

Radiation therapy billing coordination

Clinical trial billing compliance and coverage analysis

Coverage

Serving Oncology billing Teams Nationwide

We support independent practices and growing provider organizations.

Independent physician groups

Multi-location practices

Private equity backed platforms

Hospital-owned outpatient groups

Guide

The Complete Guide to Oncology billing

Oncology Billing: Drug Reimbursement and Infusion Coding

Oncology billing is among the most complex in medicine, driven by high-cost drug reimbursement, multi-hour infusion coding, and the intersection of medical and radiation therapy services. The financial stakes are significant: a single chemotherapy session can involve thousands of dollars in drug costs, and incorrect coding can mean the difference between profitability and loss for the practice.

Chemotherapy Infusion Coding

Chemotherapy infusion coding follows a hierarchical structure. The first hour of infusion is billed with 96413, and each additional hour uses 96415. When a second drug is administered sequentially after the first, the initial dose of the new agent is reported with 96417 (each additional sequential infusion). Concurrent infusions running through a separate IV line use 96415. Accurate start and stop times for each drug must be documented by the nursing staff, as payers audit infusion records to verify that billed time matches the actual administration window.

Buy-and-Bill Drug Reimbursement

The buy-and-bill model requires oncology practices to purchase chemotherapy drugs upfront and seek reimbursement after administration. Medicare reimburses physician-administered drugs at the Average Sales Price plus 6% (ASP+6%), while commercial payers negotiate their own rates. The gap between acquisition cost and reimbursement varies by drug, and practices must monitor reimbursement trends closely. Drugs with slim or negative margins can create financial pressure, particularly when payer contracts use outdated ASP data or impose sequestration reductions.

Each administered drug is billed using its specific J-code (J9XXX series for chemotherapy agents). The billed units must match the actual dosage administered, not the vial size purchased. Wasted drug from single-use vials may be reported using modifier JW, though payer policies on waste billing vary.

Radiation Therapy Billing

Intensity-modulated radiation therapy (IMRT) is billed using 77385 for simple delivery and 77386 for complex delivery. Treatment planning, simulation, and weekly management services are billed separately. Radiation oncology billing requires coordination between the treating physician, dosimetrist, and billing team to ensure that planning codes match the delivered treatment technique.

Oral Parity and Prior Authorization

Oral parity laws in many states require insurers to cover oral chemotherapy agents at the same cost-sharing level as IV chemotherapy. Practices that prescribe oral oncolytics must verify whether the patient’s plan falls under state or federal (ERISA) jurisdiction, as self-funded plans are exempt from state parity mandates.

  • Document exact start and stop times for every infusion drug to support time-based CPT code selection
  • Monitor ASP reimbursement updates quarterly to identify drugs with negative margins
  • Bill wasted single-use vial drug with modifier JW and document the discarded amount
  • Verify oral parity applicability based on the patient’s plan type before assuming equal cost-sharing
Common Questions

Frequently Asked Questions About Oncology billing

Answers to the questions practice owners ask most often.

We monitor CMS HCPCS quarterly updates and drug manufacturer notifications. When a J-code changes, we update our coding system immediately and retroactively review any claims submitted with the old code during the transition period. This prevents the revenue disruption that delayed code adoption causes.

The hierarchy determines billing order when multiple drugs are infused in one session. The primary chemotherapy infusion is billed first (96413), followed by sequential infusions (96415), with concurrent infusions last (96417). Push medications use separate codes (96409, 96411). Violating this order causes denials across the entire treatment session.

We track acquisition cost per drug, compare against payer reimbursement rates (Medicare ASP+6%, commercial contracted rates), and flag drugs where reimbursement falls below cost. This analysis helps practices make informed decisions about drug purchasing and participation in 340B or GPO programs.

Yes. Radiation oncology billing involves treatment planning codes (77261-77263), simulation (77280-77295), and daily treatment delivery codes (77385-77387 for IMRT). We coordinate radiation and medical oncology billing to ensure no claim conflicts or duplicate charges.

Oncology prior authorizations often require clinical documentation including pathology reports, staging information, genomic test results, and treatment protocol justification. We compile these documents proactively and submit authorization requests before the first treatment cycle to prevent delays.

Clinical trial billing requires separating routine care costs (billable to insurance) from investigational costs (covered by the trial sponsor). We apply the Q1 modifier for qualifying clinical trials and maintain clear documentation of which services fall under each category.

READY TO GET STARTED?

Start Billing Smarter for Oncology billing

Get a revenue review and a clear action plan tailored to your practice.

Get Your Free Assessment

HIPAA Compliant · No Upfront Fees · No Long-Term Contracts